At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
Formoterol Fumaratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg in the Treatment of Patients With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 3 clinical trial evaluating Formoterol Fumarate for COPD. Completed, across 44 sites.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2005
Primary CompletionSep 2005
First PostedSep 2005
Study CompletionSep 2006
TodayJul 2026
First PostedSep 22, 2005
Enrollment StartMar 1, 2005
Primary CompletionSep 1, 2005
Study CompletionSep 1, 2006
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 20.8 years ago
Interventions
Formoterol Fumaratedrug